Optimizing Pharmacokinetics and Pharmacodynamics of Intravenous Amikacin in Cystic Fibrosis Patients: Assessment of Clinical Outcomes and Nephrotoxicity

Cystic fibrosis is a recessive genetic disorder caused by a mutation in the cystic fibrosis transmembrane regulator gene. The mutation results in the inability to regulate chloride channels on epithelial cells, leading to inflammation, obstruction, and infection of the pulmonary tract. Declining lung function results in episodes of acute pulmonary exacerbation requiring antibiotic and airway clearance treatments. Amikacin has been used in patients who do not tolerate or are resistant to tobramycin. Amikacin is the primary aminoglycoside used for the treatment of non- tuberculosis mycobacterium. Optimal dosing regimen for amikacin remains unclear. Determine the optimal amikacin dosing regimens in cystic fibrosis patients with an acute pulmonary exacerbation. Develop a Monte Carlo simulation for amikacin dosing. Optimizing amikacin dosing to increase positive clinical outcomes and reduce nephrotoxicity.